Converging GLP-1 / tirzepatide / semaglutide / retatrutide postmarket safety signals
Key Questions
What new FDA warnings have been issued for GLP-1 drugs like semaglutide and tirzepatide?
Novo Nordisk received an FDA warning regarding unreported deaths and serious adverse events. Additional signals include 33 ileus reports with 2 deaths, plus emerging skin, hair, and cardiovascular effects.
What is 'Ozempic Personality' and is it a real side effect?
Some users of weight-loss drugs like Ozempic report reduced joy and personality changes. Doctors are evaluating these reports amid growing popularity of the medications.
What safety concerns exist with retatrutide?
Retatrutide shows an 11% GI dropout rate in trials along with skin side effects such as injection site reactions. Eli Lilly is cracking down on unapproved online sales of the drug.
Why should patients avoid compounded or unapproved GLP-1 peptides?
Unapproved peptides can cause infections, allergic reactions, or dangerous drug interactions. The FDA has issued consumer advisories highlighting these risks.
What monitoring is recommended for patients on GLP-1 medications?
Patients should monitor for NAION, GI issues, liver, and thyroid risks through systems like AEMS and FAERS. Regular medical oversight is advised amid $140B in potential indications.
How do tirzepatide and semaglutide compare in safety profiles?
Both carry risks of pancreatitis and gallbladder issues, though serious events remain rare. Monitoring for persistent nausea or severe symptoms is recommended.
Are there cardiovascular benefits associated with these drugs?
New data indicates potential CV benefits alongside the safety signals for GLP-1 agonists. These findings are emerging amid postmarket surveillance.
What actions are being taken against online sales of retatrutide?
Eli Lilly is actively warning against and cracking down on unauthorized online sales. This follows clinical trial results showing significant weight loss but also side effects.
Novo FDA warning on unreported deaths/SAEs; new ileus (33 reports/2 deaths), skin/hair effects, CV benefits. Emerging 'Ozempic Personality' reports; retatrutide 11% GI dropout. $140B indications amid compounded/unapproved peptide blocks, NAION/GI/liver/thyroid risks. Avoid unapproved; monitor AEMS/FAERS.